Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis

Emmanuel Kwateng Drokow,1 Hafiz Abdul Waqas Ahmed,1 Cecilia Amponsem-Boateng,2 Gloria Selorm Akpabla,3 Juanjuan Song,1 Mingyue Shi,1 Kai Sun11Department of Hematology, Zhengzhou University People‘s Hospital & Henan Provincial People‘s Hospital Henan, Zhengzhou, People&...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Drokow EK, Ahmed HAW, Amponsem-Boateng C, Akpabla GS, Song J, Shi M, Sun K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Autologous CD19 CAR-T haematological malignancies Response rate Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/0a5c552a7f454c9fb414c61d736147d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0a5c552a7f454c9fb414c61d736147d8
record_format	dspace
spelling	oai:doaj.org-article:0a5c552a7f454c9fb414c61d736147d82021-12-02T11:43:22ZSurvival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis1178-203Xhttps://doaj.org/article/0a5c552a7f454c9fb414c61d736147d82019-05-01T00:00:00Zhttps://www.dovepress.com/survival-outcomes-and-efficacy-of-autologous-cd19-chimeric-antigen-rec-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XEmmanuel Kwateng Drokow,1 Hafiz Abdul Waqas Ahmed,1 Cecilia Amponsem-Boateng,2 Gloria Selorm Akpabla,3 Juanjuan Song,1 Mingyue Shi,1 Kai Sun11Department of Hematology, Zhengzhou University People‘s Hospital & Henan Provincial People‘s Hospital Henan, Zhengzhou, People’s Republic of China; 2Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, People’s Republic of China; 3Department of Internal Medicine, Tianjin Medical University, Tianjin, People’s Republic of ChinaPurpose: Chimeric Antigen Receptor T(CAR-T) cell therapy is an immunotherapy approach used in treating cancer which has seen rapid development over the decades. It becomes the preferred treatment choice after patients have failed conventional chemotherapy.Methods: We conducted a meta-analysis in 320 patients from 14 studies to estimate the survival outcome, response rate and toxicity of autologous CD19 CAR-T cell therapy and predict other factors associated with a better prognosis.Results: The overall response rate was 71.88% (95% CI: 61.34–80.46%, p<0.01) and CRS toxicity was 60.15% (95% CI: 42.87–75.22%, p<0.01). Patients who received lymphodepletion was associated with a better response rate (77%, 95%CI: 67–83%; p-value =0.001) in comparison to the other patients who did not (66%, 95%CI: 41–83%).Conclusion: Lymphodepletion regimen may play a crucial role in predicting the prognosis of patients with hematological malignancies. Lymphodepletion patients had better progression-free survival than those who did not.Keywords: autologous, CD19, CAR-T, hematological malignancies, response rateDrokow EKAhmed HAWAmponsem-Boateng CAkpabla GSSong JShi MSun KDove Medical PressarticleAutologousCD19CAR-Thaematological malignanciesResponse rateTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 15, Pp 637-646 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Autologous CD19 CAR-T haematological malignancies Response rate Therapeutics. Pharmacology RM1-950
spellingShingle	Autologous CD19 CAR-T haematological malignancies Response rate Therapeutics. Pharmacology RM1-950 Drokow EK Ahmed HAW Amponsem-Boateng C Akpabla GS Song J Shi M Sun K Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis
description	Emmanuel Kwateng Drokow,1 Hafiz Abdul Waqas Ahmed,1 Cecilia Amponsem-Boateng,2 Gloria Selorm Akpabla,3 Juanjuan Song,1 Mingyue Shi,1 Kai Sun11Department of Hematology, Zhengzhou University People‘s Hospital & Henan Provincial People‘s Hospital Henan, Zhengzhou, People’s Republic of China; 2Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, People’s Republic of China; 3Department of Internal Medicine, Tianjin Medical University, Tianjin, People’s Republic of ChinaPurpose: Chimeric Antigen Receptor T(CAR-T) cell therapy is an immunotherapy approach used in treating cancer which has seen rapid development over the decades. It becomes the preferred treatment choice after patients have failed conventional chemotherapy.Methods: We conducted a meta-analysis in 320 patients from 14 studies to estimate the survival outcome, response rate and toxicity of autologous CD19 CAR-T cell therapy and predict other factors associated with a better prognosis.Results: The overall response rate was 71.88% (95% CI: 61.34–80.46%, p<0.01) and CRS toxicity was 60.15% (95% CI: 42.87–75.22%, p<0.01). Patients who received lymphodepletion was associated with a better response rate (77%, 95%CI: 67–83%; p-value =0.001) in comparison to the other patients who did not (66%, 95%CI: 41–83%).Conclusion: Lymphodepletion regimen may play a crucial role in predicting the prognosis of patients with hematological malignancies. Lymphodepletion patients had better progression-free survival than those who did not.Keywords: autologous, CD19, CAR-T, hematological malignancies, response rate
format	article
author	Drokow EK Ahmed HAW Amponsem-Boateng C Akpabla GS Song J Shi M Sun K
author_facet	Drokow EK Ahmed HAW Amponsem-Boateng C Akpabla GS Song J Shi M Sun K
author_sort	Drokow EK
title	Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis
title_short	Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis
title_full	Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis
title_fullStr	Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis
title_full_unstemmed	Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis
title_sort	survival outcomes and efficacy of autologous cd19 chimeric antigen receptor-t cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/0a5c552a7f454c9fb414c61d736147d8
work_keys_str_mv	AT drokowek survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT ahmedhaw survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT amponsemboatengc survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT akpablags survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT songj survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT shim survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis AT sunk survivaloutcomesandefficacyofautologouscd19chimericantigenreceptortcelltherapyinthepatientwithdiagnosedhematologicalmalignanciesasystematicreviewandmetaanalysis
_version_	1718395323556036608

Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis

Ejemplares similares